Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-linked glycosylation
- Molecular classification
- Post-translational modification, Protein modification pathway, Glycosylation process
01
Overview
N-linked glycosylation is a co- and post-translational modification pathway in which complex oligosaccharides (glycans) are covalently attached to the nitrogen atom of asparagine residues in proteins, predominantly at the consensus sequence Asn-X-Ser/Thr (where X ≠ proline)[1][4][5][7]. The process begins in the endoplasmic reticulum and continues in the Golgi apparatus, involving a highly regulated assembly and remodeling of glycans by dozens of enzymes. N-linked glycosylation profoundly influences protein folding, structural stability, sorting, cell surface recognition, immune responses, and intercellular signaling[2][3][4][6][7]. Aberrant N-linked glycosylation patterns are implicated in various diseases, including congenital glycosylation disorders, cancer, neurological diseases, and infections, reflecting its fundamental role in cell and tissue physiology[2][3][4].
- Other names
- N-glycosylationN-linked protein glycosylationN-glycan synthesis
02
Mechanism of action
Inhibition of glycosyltransferases or oligosaccharyltransferase (blocks glycan attachment, e.g., tunicamycin) Modulation of glycan branching or structure (affecting downstream signaling or recognition)
03
Biological functions
Protein folding and quality controlStabilization of protein structureRegulation of protein trafficking and subcellular localizationCell-cell communication and signalingModulation of immune response, including receptor signaling and antibody functionSignal transductionNeurotransmitter receptor regulationProtein-protein interactions
04
Disease associations
Neurological disorders (due to altered neural glycosylation and signaling)Congenital disorders of glycosylationCancer (altered glycan profiles modulate cell signaling, metastasis, and immune evasion)Infections (critical for viral entry, immune responses, pathogen glycoprotein function)Autoimmune diseases (altered immune glycosylation recognition)Other
05
Safety considerations
Systemic inhibition or alteration of N-linked glycosylation can cause severe toxicity due to disruption of essential protein folding, trafficking, and functionGlycosylation inhibitors are generally not selective and thus are not suitable for clinical use except in special research contexts
06
Biomarkers
Glycan profile analysis on serum or tissue glycoproteins (used in diagnostics, disease subtyping, and monitoring therapeutic antibodies, as glycosylation affects antibody function)Lectin binding patterns
Beyond the preview
Go deeper on N-linked glycosylation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-linked glycosylation.